🔴 Incyte is trading 4.2% down today on profit-taking after post-earnings surge

Incyte is trading 4.2% down at $121.81 as the stock undergoes a period of normalization and profit-taking following a sharp two-day rally.

• The stock previously jumped 9–11% on July 28, driven by raised guidance and a CMS-related Opzelura settlement.
• Investor sentiment was further bolstered earlier this week by positive analyst upgrades and optimism surrounding the company's drug pipeline.
• Today's decline marks a cooling-off period as the market stabilizes after the significant post-earnings spike.